RxDoctor Payments Data

Justin Pi, MD

Pulmonary Disease · Newark, NJNPI 1427203306

Payments from drug & device makers

$5,247in general payments, 2019–2025

Across 338 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$828
  • AstraZeneca$489
  • Harmony Biosciences LLC$469
  • Jazz Pharmaceuticals Inc.$431
  • Sunovion Pharmaceuticals Inc.$309
  • Axsome Therapeutics, Inc.$290
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,90493%
  • Education$3437%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,247 in reported general payments places this provider in the 65th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$134,226
Medicare patients
647
Services billed
1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$62,170
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$22,518
EliquisApixaban11$13,179
NeuproRotigotine12$9,840
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,159
Breo ElliptaFluticasone/Vilanterol14$5,819
Albuterol Sulfate HfaAlbuterol Sulfate62$1,610
Ventolin HfaAlbuterol Sulfate17$900
Trazodone Hcl94$479
Baclofen12$410
Azelastine Hcl12$393
Alprazolam39$284
Zolpidem Tartrate54$245
Gabapentin14$181
Montelukast Sodium11$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$828$77,148113 claims
AstraZenecaBreztri Aerosphere$489$22,51835 claims
PfizerEliquis$25$13,17911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →